We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
126
Clearline Capital
New York
$1.35M +$1.41M +32,961 New
GLA
127
Great Lakes Advisors
Illinois
$1.34M +$269K +6,296 +24%
BC
128
BIT Capital
Germany
$1.33M -$373K -8,745 -21%
SAM
129
Simplify Asset Management
Nevada
$1.26M -$4.36K -102 -0.3%
Ensign Peak Advisors
130
Ensign Peak Advisors
Utah
$1.2M – – –
Wells Fargo
131
Wells Fargo
California
$1.19M -$109K -2,549 -8%
JF
132
Jump Financial
Illinois
$1.12M +$1.17M +27,289 New
Envestnet Asset Management
133
Envestnet Asset Management
Illinois
$1.09M -$115K -2,688 -9%
Canada Life
134
Canada Life
Manitoba, Canada
$1.08M -$51.8K -1,213 -4%
P8IP
135
Pier 88 Investment Partners
California
$1.07M +$457K +10,700 +70%
Susquehanna International Group
136
Susquehanna International Group
Pennsylvania
$1.02M -$1.03M -24,079 -49%
BMSSC
137
B. Metzler seel. Sohn & Co
Germany
$979K – – –
PA
138
Profund Advisors
Maryland
$921K -$217K -5,083 -18%
Stifel Financial
139
Stifel Financial
Missouri
$897K +$361K +8,461 +63%
Handelsbanken Fonder
140
Handelsbanken Fonder
Sweden
$876K +$286K +6,700 +46%
ASRS
141
Arizona State Retirement System
Arizona
$853K +$18.5K +434 +2%
RJA
142
Raymond James & Associates
Florida
$849K +$6.15K +144 +0.7%
Citigroup
143
Citigroup
New York
$842K -$5.82M -136,374 -87%
SCI
144
S&CO Inc
Massachusetts
$832K +$865K +20,255 New
MS
145
Maven Securities
Jersey
$822K +$427K +10,000 +100%
GGHC
146
Gilder Gagnon Howe & Co
New York
$819K +$107K +2,504 +14%
ECU
147
Eisler Capital (US)
New York
$818K +$197K +4,611 +30%
ORI
148
Oak Ridge Investments
Illinois
$795K +$826K +19,350 New
ACM
149
Aquatic Capital Management
Illinois
$781K -$51.2K -1,200 -6%
TI
150
Trexquant Investment
Connecticut
$771K -$1.9M -44,398 -70%
4 5
6
7 8

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.